Harbin Pharmaceutical Group Co Ltd banner

Harbin Pharmaceutical Group Co Ltd
SSE:600664

Watchlist Manager
Harbin Pharmaceutical Group Co Ltd Logo
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Watchlist
Price: 3.51 CNY Market Closed
Market Cap: ¥8.8B

Operating Margin

4.3%
Current
Declining
by 0.6%
vs 3-y average of 4.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
4.3%
=
Operating Income
¥689.4m
/
Revenue
¥15.9B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
4.3%
=
Operating Income
¥689.4m
/
Revenue
¥15.9B

Peer Comparison

Country Company Market Cap Operating
Margin
CN
Harbin Pharmaceutical Group Co Ltd
SSE:600664
8.8B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
997.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
578.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
281.1B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
303.5B USD
Loading...
CH
Novartis AG
SIX:NOVN
230.9B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
154.7B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD
Loading...

Market Distribution

In line with most companies in China
Percentile
50th
Based on 8 544 companies
50th percentile
4.3%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

Harbin Pharmaceutical Group Co Ltd
Glance View

Market Cap
8.8B CNY
Industry
Pharmaceuticals

Founded amidst the industrial boom of the 1950s, Harbin Pharmaceutical Group Co., Ltd. has evolved into one of China's pharmaceutical giants, headquartered in Harbin, Heilongjiang Province. Historically grounded in traditional Chinese medicine, it has grown into a multifaceted enterprise that blends its cultural heritage with modern pharmaceutical science. Harbin Pharma's journey from its humble beginnings to becoming a household name is marked by its robust research and development efforts, which are key to its operations. The company's vertical integration strategy stretches through the entire pharmaceutical value chain, encompassing research, production, and distribution, thereby optimizing efficiency and maintaining quality control across its vast product lines. This structure not only helps minimize costs but also allows Harbin Pharma to quickly adapt to changes in the healthcare market. The company primarily generates revenue through the production and sale of both prescription and over-the-counter drugs, catering to a diverse array of health needs globally. A significant portion of its income stems from the manufacture of antibiotics, patent drugs, and biological products, though it also maintains a strong presence in the consumer health sector with vitamins and dietary supplements. Strategically, Harbin Pharma leverages its extensive distribution network, one of the largest in China, ensuring that its products reach even the most remote areas. Moreover, the company benefits from partnerships and collaborations with international pharmaceutical companies, which allow it to expand its global footprint and enhance its product offerings. In essence, Harbin Pharmaceutical Group's success is anchored in its adaptive business strategies, commitment to innovation, and ability to navigate the complexities of the rapidly evolving pharmaceutical landscape.

Intrinsic Value
6.24 CNY
Undervaluation 44%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
4.3%
=
Operating Income
¥689.4m
/
Revenue
¥15.9B
What is Harbin Pharmaceutical Group Co Ltd's current Operating Margin?

The current Operating Margin for Harbin Pharmaceutical Group Co Ltd is 4.3%, which is below its 3-year median of 4.9%.

How has Operating Margin changed over time?

Over the last 3 years, Harbin Pharmaceutical Group Co Ltd’s Operating Margin has increased from 1.6% to 4.3%. During this period, it reached a low of 1.6% on Aug 30, 2022 and a high of 6% on Dec 31, 2024.

Back to Top